Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03616041 · ClinicalTrials.gov registry record
Capsule Endoscopy for Severe Hematochezia
A clinical trial of Hematochezia, sponsored by CURE Digestive Diseases Research Center.
- Recruiting
- Registry status
- 23
- Enrollment target
- 2
- Study locations
NCT03616041: Recruiting study of Hematochezia, sponsored by CURE Digestive Diseases Research Center.
NCT03616041 is a study of Hematochezia that is actively recruiting participants, run by CURE Digestive Diseases Research Center. The registered enrollment target is 23 participants. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03616041, a study of Hematochezia, is actively recruiting participants, sponsored by CURE Digestive Diseases Research Center.
- RECRUITING
- Registry status
- 23 participants
- Enrollment target
- 2
- Study locations
Study Summary
Patients with severe hematochezia (bright red blood per rectum) may have a bleeding source proximal to the colon. Visualization of the entire gastrointestinal tract using a second-generation colon capsule endoscopy system could improve diagnostic yields and form the basis for a new approach to early diagnosis that could change guidelines and practice management in these patients. The hypothesis of this study is that urgent colon capsule endoscopy will have higher rates of lesion localization and diagnosis and reduced time to diagnosis than the standard tagged red blood cell scanning and/or angiography. In this study, the eligible patients with severe hematochezia are enrolled to undergo an evaluation with the capsule endoscopy in addition to the standard tests including a tagged RBC scan and/or an angiogram. The outcomes in terms of diagnostic yields of the capsule endoscopy will be compared to the standard tests.
Conditions Studied
Interventions
- DEVICE Second-generation colon capsule endoscopy system
Study Locations (2)
California
- VA Greater Los Angeles Healthcare System - Los Angeles
- Ronald Reagan UCLA Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2021-02-10 |
| Est. Completion | 2024-12-31 |
What NCT03616041 shows while recruiting
NCT03616041 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 1 condition, with Hematochezia appearing as the primary indexed condition, and to 1 intervention - of which Second-generation colon capsule endoscopy system is the first listed.
NCT03616041 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03616041 about?
NCT03616041 is a clinical study titled "Capsule Endoscopy for Severe Hematochezia". Patients with severe hematochezia (bright red blood per rectum) may have a bleeding source proximal to the colon. Visualization of the entire gastrointestinal tract using a second-generation colon capsule endoscopy system could improve diagnostic yields and form the basis for a new approach to early...
What is the current status of trial NCT03616041?
This trial is currently recruiting. The enrollment target is 23 participants. The study started on 2021-02-10. Estimated completion is 2024-12-31.
What conditions does trial NCT03616041 study?
This clinical trial studies the following conditions: Hematochezia.
What interventions are being tested in trial NCT03616041?
The interventions under investigation include: Second-generation colon capsule endoscopy system (DEVICE).
Who is sponsoring clinical trial NCT03616041?
This trial is sponsored by CURE Digestive Diseases Research Center, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03616041 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematochezia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
- NCT04796012 · 23 participants · Phase 1
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI